- Home
- ACAD vs ORLA Comparison
ACAD vs ORLA Comparison
Compare ACAD & ORLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACAD | ORLA |
|---|---|---|
| Founded | 1993 | 2007 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.0B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACAD | ORLA |
|---|---|---|
| Price | $25.71 | $19.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 1 |
| Target Price | ★ $30.00 | $27.00 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 02-25-2026 | 03-19-2026 |
| Dividend Yield | N/A | ★ 0.08% |
| EPS Growth | 98.53 | ★ 2239.45 |
| EPS | ★ 1.54 | 0.16 |
| Revenue | ★ $1,047,118,000.00 | $772,153,000.00 |
| Revenue This Year | $15.16 | $183.80 |
| Revenue Next Year | $11.79 | $36.88 |
| P/E Ratio | ★ $17.00 | $118.59 |
| Revenue Growth | 12.69 | ★ 145.83 |
| 52 Week Low | $13.40 | $5.77 |
| 52 Week High | $28.35 | $19.87 |
Technical Indicators
Market Signals| Indicator | ACAD | ORLA |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 80.35 |
| Support Level | $25.25 | $17.95 |
| Resistance Level | $27.22 | $19.87 |
| Average True Range (ATR) | 0.95 | 0.89 |
| MACD | -0.13 | 0.44 |
| Stochastic Oscillator | 18.16 | 94.90 |
Price Performance
Historical ComparisonAbout ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About ORLA Orla Mining Ltd.
Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects; the Camino Rojo gold and silver project in Zacatecas State, Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.